SARS CoV 2 News and Research

RSS

Researchers receive €2.35 million to examine disease pathways of viruses

Two University College Dublin (UCD) researchers and SiriusXT, a UCD spin-out company, have been awarded a total of €2.35 million in funding for a disruptive photonics technology project, through Horizon 2020, the EU's research and innovation programme, to examine the disease pathways of viruses.

9 Oct 2020

New study examines relationship between ethnic background and SARS-CoV-2 virus

Patients of Black ethnicity have an increased risk of requiring hospital admission for COVID-19, while patients of Asian ethnicity have an increased risk of dying in hospital from COVID-19, compared to White patients, a study has found.

9 Oct 2020

Long-lasting antibodies detected in blood and saliva of COVID-19 patients

Two separate studies have documented the persistence of antibodies that target SARS-CoV-2 in hundreds of patients with COVID-19 at least 3 months after symptom onset.

9 Oct 2020

New model can simulate and analyze large number of viral infections

It is only 120 millionths of a millimetre in size but can bring entire countries to a standstill: the Corona virus. Even if it were to disappear one day, viral infections will still be among the most frequent and difficult-to-treat diseases in humans.

9 Oct 2020

86 percent of the UK's COVID-19 patients have no symptoms

Many people who contract the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19), develop only mild and moderate symptoms. A small fraction of those infected develop severe symptoms, which usually occur in people who are at higher risk due to comorbidities.

9 Oct 2020

University of Minnesota Medical School chosen as ‘Capacity Building Center’ for national network

The University of Minnesota Medical School's Department of Laboratory Medicine and Pathology has been selected to participate in a new national network dedicated to serological, or antibody, sciences as one of four Capacity Building Centers in the country.

9 Oct 2020

Clear and unequivocal evidence we should washing our hands during COVID-19

The study shows that Americans are washing their hands much more they did before the coronavirus pandemic. However, the groups who are less likely to remember to wash their hands on multiple occasions were white people, men, and those between the ages of 18 and 24.

9 Oct 2020

Mass production of SARS-CoV-2 ORF8 protein using a chemical-inducible system in tobacco BY-2 cells

Researchers from the Japan Advanced Institute of Science and Technology (JAIST) and Ishikawa Prefectural University, Japan, recently attempted to synthesize the ORF8 protein with the help of a chemical-inducible protein production system using tobacco BY-2 cells. This study has been published demonstrated in the preprint server, bioRxiv.

9 Oct 2020

Virginia Tech to build a cyberinfrastructure for wastewater antibiotic-resistant gene monitoring

Antibiotic resistance is a grand challenge of the 21st century. According to the U.S. Centers for Disease Control and Prevention, antibiotic resistance rates are increasing globally, with an estimated 35,000 related deaths per year in the United States in 2019, compared to 23,000 in 2013.

8 Oct 2020

Mount Sinai to receive more than $7.3 million as part of NCI's new Serological Sciences Network

Researchers from the Icahn School of Medicine at Mount Sinai will receive more than $7.3 million from the National Cancer Institute as part of the NCI's new Serological Sciences Network (SeroNet), one of the largest coordinated national efforts to study immunology and SARS-CoV-2, the virus that causes COVID-19.

8 Oct 2020

Certain pre-existing conditions may highly increase a patient's risk of dying from COVID-19

A large, international study of COVID-19 patients confirmed that cardiovascular disease, hypertension, diabetes, congestive heart failure, chronic kidney disease, stroke and cancer can increase a patient's risk of dying from the virus.

8 Oct 2020

NIH clinical trial to test a combination treatment regimen for COVID-19

A clinical trial to test the safety, tolerability and efficacy of a combination treatment regimen for coronavirus disease 2019 (COVID-19) consisting of the antiviral remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, has begun.

8 Oct 2020

SARS-CoV-2 survives on human skin for 9 hours

Japanese researchers have now studied the survival possibilities of the flu virus and the SARS-CoV-2 on human skin. Their study titled, "Survival of SARS-CoV-2 and influenza virus on the human skin: Importance of hand hygiene in COVID-19," was published in the latest issue of the journal Clinical Infectious Diseases.

8 Oct 2020

Detection of SARS-CoV-2 viral persistence in built environments

In a recent paper in an open-access journal, mSystems, published by The American Society for Microbiology, Ceth W. Parker et al. show challenges in recovering the virus, change in infectivity, and the case of viral persistence in built environments.

8 Oct 2020

Scientists refine SARS-CoV-2 protein structures

An international team of scientists has developed computational models to re-analyze and validate experimentally-derived publicly available macromolecular structures of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 Oct 2020

Overreaction of the immune system could be linked to severe COVID-19 cases

Samples from the lungs of patients show a runaway immune system reaction could be one mechanism behind severe COVID-19 cases.

8 Oct 2020

Face masks far more protective against COVID-19 than face shields, CDC experts

Researchers from the Centers for Disease Control and Prevention (CDC) have conducted a study showing that face masks and neck gaiters appear to be much more effective than face shields at reducing the expulsion of respiratory aerosols that could potentially transmit severe acute respiratory syndrome 2 (SARS-CoV-2).

8 Oct 2020

Neutralizing responses to infection relatively common in COVID-19

A new study has shown that severe coronavirus disease 2019 (COVID-19) is associated with unique B cell receptor (BCR) signatures and multiclonal neutralizing responses against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 Oct 2020

Leopoldina appeals to governments to take protective measures on COVID-19 pandemic

Since the end of July, the number of new infections with the coronavirus has been on the rise again in Germany.

8 Oct 2020

Researchers identify a promising method to stop COVID-19 infection

While the world waits eagerly for a safe and effective vaccine to prevent infections from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus behind the COVID-19 pandemic, researchers also are focusing on better understanding how SARS-CoV-2 attacks the body in the search for other means of stopping its devastating impact.

8 Oct 2020